Clinical Trials Sponsored by Kolon Life Science

Total 837 results

Power Life Sciences Inc.

Not yet recruiting

Exploring Engagement Dynamics Among Individuals Impacted by Bladder Cancer

Bladder Cancer

United States
Power Life Sciences Inc.

Not yet recruiting

A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients

Metastatic Prostate Cancer

United States
Power Life Sciences Inc.

Not yet recruiting

A Close Examination of Patient Experiences in Cluster Headache Clinical Research

Cluster Headache

United States
Power Life Sciences Inc.

Not yet recruiting

Patient Perspectives in Squamous Cell Carcinoma Clinical Trials

Squamous Cell Carcinoma

United States
Power Life Sciences Inc.

Not yet recruiting

Unveiling Patient Experiences in Testicular Cancer Clinical Trials

Testicular Cancer

United States
Power Life Sciences Inc.

Not yet recruiting

Determining Patterns In Study Experiences of Neuroblastoma Patients

Neuroblastoma

United States
Power Life Sciences Inc.

Not yet recruiting

Discovering Factors in Narcolepsy Patients' Clinical Research Experiences

Narcolepsy
Power Life Sciences Inc.

Not yet recruiting

Discovering Factors in the Clinical Trial Journey of Dementia Patients

Dementia
Power Life Sciences Inc.

Not yet recruiting

Assessing Factors in Tinnitus Patients' Clinical Study Experiences

Tinnitus
Power Life Sciences Inc.

Not yet recruiting

Appraising Medical Trial Experiences of Ovarian Cancer Patients

Ovarian Cancer
Power Life Sciences Inc.

Not yet recruiting

Discovering Factors in Cervical Cancer Patients' Clinical Trial Experiences

Cervical Cancer
Kezar Life Sciences, Inc.

Recruiting

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Lupus Nephritis

United States, Korea, Republic of, Australia, Malaysia, Taiwan, South Africa, Singapore, United Kingdom, Puerto Rico, Croatia, India, Greece, Spain, Brazil, Philippines, Guatemala, Argentina, Portugal
Power Life Sciences Inc.

Not yet recruiting

Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials

Breast Cancer | Triple Negative Breast Cancer
Power Life Sciences Inc.

Not yet recruiting

Assessment of Rosacea Patients' Clinical Trial Experiences

Rosacea
Power Life Sciences Inc.

Not yet recruiting

Analyzing Clinical Trial Experiences of Colon Cancer Patients

Colon Cancer | Colon Disease
Power Life Sciences Inc.

Not yet recruiting

Looking At Bile Duct Cancer Patient Experience Patterns in Medical Trials

Bile Duct Cancer
Power Life Sciences Inc.

Not yet recruiting

Exploring Clinical Trial Experiences of Patients With Migraine

Migraine | Migraine Disorders
Power Life Sciences Inc.

Not yet recruiting

Exploring Clinical Trial Experiences of People With Leiomyosarcoma

Leiomyosarcoma
Power Life Sciences Inc.

Not yet recruiting

Finding Patterns In Clinical Study Experiences of Multiple Sclerosis Patients

Multiple Sclerosis
Power Life Sciences Inc.

Not yet recruiting

Analyzing Orthopedic Patient Experience Patterns in Medical Trials

Orthopedic Disorder
Wave Life Sciences Ltd.

Recruiting

Study of WVE-003 in Patients With Huntington's Disease

Huntington Disease

Canada, Spain, Australia, Denmark, Netherlands, Poland, United Kingdom, France, Germany, Italy
Avacta Life Sciences Ltd

Recruiting

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Soft Tissue Sarcoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Biliary Tract Cancer | Oesophageal Cancer | Cancer of Unknown Primary Site

United States, United Kingdom
Kezar Life Sciences, Inc.

Completed

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis (PRESIDIO)

Dermatomyositis | Polymyositis

United States, Czechia, Germany
Dharma Life Sciences LLC

Completed

Reducing Anxiety Levels Through the Dharma Life App-Based and Mentor-Based Program Targeting Personality Characteristics: A Randomized Control Trial

Anxiety

United States
Banner Life Sciences LLC

Enrolling by invitation

Observational Study of Persistence on Bafiertam Treatment In Routine Clinical Practice (SIMPLE)

Relapsing Remitting Multiple Sclerosis

United States, Puerto Rico
Kezar Life Sciences, Inc.

Completed

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

Dermatomyositis | Polymyositis

United States
Banner Life Sciences LLC

Completed

Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects

Relapsing Remitting Multiple Sclerosis
Tiziana Life Sciences LTD

Withdrawn

A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease

Crohn's Disease
Verily Life Sciences LLC

Completed

Baseline Sleep Apnea Study #2

Obstructive Sleep Apnea of Adult

United States
Suven Life Sciences Limited

No longer available

Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy

Narcolepsy
Wave Life Sciences Ltd.

Terminated

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease (PRECISION-HD2)

Huntington's Disease

United States, Denmark, Canada, Australia, United Kingdom, France, Germany, Poland
Tiziana Life Sciences LTD

Withdrawn

Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
Wave Life Sciences Ltd.

Terminated

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Huntington Disease

Denmark, Australia, Canada, France, United Kingdom, Germany, Poland
ReAlta Life Sciences, Inc.

Withdrawn

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

COVID-19 | Acute Lung Injury | ALI

United States
Banner Life Sciences LLC

Withdrawn

Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate (PERSIST)

Relapsing Remitting Multiple Sclerosis
Tiziana Life Sciences LTD

Completed

Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

Israel, Greece, Italy
Wave Life Sciences Ltd.

Terminated

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)

Duchenne Muscular Dystrophy

United States, Belgium, United Kingdom, Czechia, Canada, France, Italy, Sweden
Suven Life Sciences Limited

No longer available

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease (SUVN-502)

Dementia | Alzheimer Disease | Cognition Disorders
Banner Life Sciences LLC

Completed

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

Multiple Sclerosis

United States
Sellas Life Sciences Group

Unknown

WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

Multiple Myeloma | Minimal Residual Disease | High-Risk Cancer

United States
Sellas Life Sciences Group

Completed

WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
CANbridge Life Sciences Ltd.

Completed

A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme

Glioblastoma Multiforme

Taiwan
Suven Life Sciences Limited

Completed

Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects (SUVN-911)

Major Depressive Disorder

United States
Sprim Advanced Life Sciences

Completed

Immune Response to the Consumption of Lactobacillus GG and FOS in Patients With Recurrent Herpes Labialis (EVIM)

Herpes Labialis
CANbridge Life Sciences Ltd.

Unknown

CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

Glioblastoma
Bioniche Life Sciences Inc.

Terminated

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (EMBARC-RF)

Carcinoma in Situ | Neoplasm Recurrence, Local | Bladder Neoplasm | Mycobacterium | Transitional Cell, Carcinoma

United States, Canada, Poland, Germany, Netherlands, United Kingdom
Suven Life Sciences Limited

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

Cognitive Disorders

United States
Bioniche Life Sciences Inc.

Withdrawn

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Bladder Cancer

United States
Alltech Life Sciences Inc.

Completed

Safety and Tolerability of Antioxidant (AT-001)for Reducing Brain Oxidative Stress

Oxidative Stress

United States
Afexa Life Sciences Inc

Terminated

GLU-xx Formulations in Individuals With Impaired Glucose Tolerance

Impaired Glucose Tolerance

United States

Clinical Trials Sponsored by Kolon Life Science

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations